🚨Publication alert🚨
@AGA_GHAdvances#MASLD in #HIV affects more than the liver, it impacts quality of life.
In our study (n=519), MASLD was linked to worse physical health, fatigue & emotional well-being.
Metabolic burden & fibrosis worsened outcomes.
👉ghadvances.org/article/S2772…
Humbled and honoured to begin my mandate as CASL President 🙏
"The Miracle Worker" has inspired me since childhood as a powerful story of courage, resilience, and hope🌟💪—values that continue to guide me today.
I look forward to working together to advance our shared mission🌍
📢 New paper in @JHEP_Reports👏
Pleased to co-author this global survey on the humanistic & societal burden of #MASH, with outstanding colleagues.
🩺 Advanced fibrosis → worse quality of life
💼 Reduced work productivity
🏥 Higher healthcare utilization
👉jhep-reports.eu/article/S258…
After an intense weekend at the @cddw_clm conference, where I began my mandate as President of #CASL, I relaxed by watching #ThePrestige with my son!
Research can feel like magic🎩
Years of trying, testing, failing, trying again.. until your prestige finally appears! @CASLupdates
🚨Proud to co-author this New publication in #Gut🚨
🟠This International Delphi consensus confirms the link between #MASLD and colorectal cancer.
✅Call for earlier, risk-adapted screening and integrated metabolic care.
👉 lnkd.in/gbMdXUG2#Hepatology#ColorectalCancer
Proud to co-author this Review just published in @LancetGastroHep
🧬We highlight liver health disparities in #transgender and gender diverse populations, review the hepatic safety of modern gender-affirming hormone therapy, and call for inclusive, evidence-based #Hepatology care
Calling all Family Physicians! 👩⚕️👨⚕️
Join us virtually on Jan 29 for a program exploring the latest Diabetes Canada & Obesity Canada updates on CKD, MASLD & obesity pharmacotherapy.
💻Live Zoom Webinar
👉Register: imedicus.zoom.us/webinar/reg…
🇨🇦 Big step for liver health in Canada: I was interviewed following Health Canada’s approval of Wegovy® (semaglutide) as pharmacotherapy for #MASH.
This marks an important shift toward recognizing MASH as a complex metabolic disease—beyond lifestyle alone.
healthing.ca/liver-diseases/…
Grateful to be at The #LiverMeeting ✨
🍽️🤝Enjoyed a lovely lunch with colleagues — the kind of conversation that fuels new ideas and reminds me why our community is so special
🎓 Proud to see posters from my talented trainees on display, on #MASLD in #HIV and #IBD📊
#TLM2025
Honoured to join the Global Metabolic Health roundtable at the United Nations General Assembly #UNGA80 in New York🌍
#MASLD/#MASH & Non-Communicable diseases in focus
🔬Leaders across liver, diabetes, obesity & patient voices united to elevate #LiverHealth on the #NCDs agenda🚀
🎉 Excited to celebrate the first impact factor of the Canadian Liver Journal!
📖 The voice of #CASL & Canadian #hepatology
🌍 Open access, global reach
👉 Submit your next paper to the Canadian Liver Journal & join us in advancing #liver health!
🔗 doi.org/10.3138/canlivj-2025…
🚨Honoured and grateful!🚨
Thrilled to receive the 2025 Montreal General Hospital Research Awards, recognizing my work on fatty #liver in people with inflammatory #bowel disease.
🙏 Deeply thankful to the Fondation de l'Hôpital général de Montréal and its benefactors. #MASLD#IBD
📢New paper out!
In people with #HIV, severity of #MASLD is linked to a distinct gut #microbiota signature 🦠—but not functional pathway shifts.
🎯Microbial profiling could complement #noninvasive risk stratification for #liver disease in this group.
🔗mdpi.com/1422-0067/26/17/816…